SAN DIEGO, March 28, 2011 /PRNewswire/ — Optimer
Pharmaceuticals, Inc. (Nasdaq:
OPTR) announced that data highlighting the burden of
Clostridium difficile infection using National health
insurance claims and survey databases will be presented on
April 2, 2011 at the 21st Annual Scientific Meeting of The
Society for Healthcare Epidemiology of America (SHEA).
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster
Presentation Information:Title:
Rates of Recurrence and Mortality among Patients with a
Diagnosis of Clostridium Difficile Infection in the United
States: An Analysis Using National Health Insurance Claims and
Survey DatabasesPresenter:
Erik R. Dubberke, MD, MSPH, Washington University School of
Medicine, St. Louis, MODate:
Saturday, April 2, 2011 Time:
1:00 p.m. to 2:15 p.m. Central TimeLocation:
Hilton Anatole Hotel, Trinity Ballroom, Dallas,
TexasPresentation #:
152About OptimerOptimer Pharmaceuticals, Inc. is a
biopharmaceutical company focused on discovering, developing and
commercializing innovative hospital specialty products that have a
positive impact on society. Optimer has two anti-infective product
candidates in development, fidaxomicin and Pruvel™
(prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being
developed for the treatment of Clostridium difficile
infection (CDI). The FDA granted the Company’s request for
six-month Priority Review of fidaxomicin, and has assigned a
Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011.
The Company also filed a MAA with the European Medicines Agency
(EMA) for fidaxomicin. Pruvel™ is a prodrug in the
fluoroquinolone class of antibiotics being developed as a treatment
f
‘/>”/>
SOURCE